PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

How the Biopharmaceutical Industry is Responding to Patient Demand for Injection Alternatives

Biologics represent a powerful and innovative class of therapeutics in the fight against chronic disease and their sales are projected to reach $326 billion by 2022 – roughly 30% of global prescription drug sales. Biologics tend to be highly selective, effective, and have fewer side-effects than conventional drugs. However, their chemical structure makes them challenging to administer using oral delivery, so the accepted standard of care is needle-based delivery methods, particularly intravenous injection. Christophe Pierlot of Pall Biotech discusses how subcutaneous delivery will become a routine option for both novel and legacy drugs.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/How-the-Biopharmaceutical-Industry-is-Responding-to.pdf”]

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Drug Discovery 2025, ELRIG – 04.07.2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025